{"version":"1.0","provider_name":"cometis AG","provider_url":"https:\/\/www.cometis.de\/de\/","title":"15. Januar 2018 | Dermapharm Holding SE: plant B\u00f6rsengang","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ZaoJwg5DaZ\"><a href=\"https:\/\/www.cometis.de\/de\/15-januar-2018-dermapharm-holding-se-plant-boersengang\/\">15. Januar 2018 | Dermapharm Holding SE: plant B\u00f6rsengang<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.cometis.de\/de\/15-januar-2018-dermapharm-holding-se-plant-boersengang\/embed\/#?secret=ZaoJwg5DaZ\" width=\"600\" height=\"338\" title=\"&#8222;15. Januar 2018 | Dermapharm Holding SE: plant B\u00f6rsengang&#8220; &#8211; cometis AG\" data-secret=\"ZaoJwg5DaZ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.cometis.de\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","thumbnail_width":171,"thumbnail_height":31,"description":"Corporate News zum Archiv &nbsp; Dermapharm Holding SE: plant B\u00f6rsengang &nbsp; \u00bb Ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete in Deutschland plant einen B\u00f6rsengang im regulierten Markt (Prime Standard) der Frankfurter Wertpapierb\u00f6rse \u00bb Zur Finanzierung der Wachstumsstrategie plant Dermapharm eine Kapitalerh\u00f6hung mit einem Bruttoemissionserl\u00f6s von ca. 100 Mio. Euro \u00bb Zus\u00e4tzlich zu der [&hellip;]"}